Answers are grounded in this paper and cite their sources.
In the January 2011 issue of this journal, Swedish authors described three severe cases of predominantly pulmonary infection with the European hantavirus Puumala virus (PUUV), leading to death due to refractory shock in two of these patients [1]. Of note, the kidneys in these two fatal cases had, on autopsy, no prominent inflammatory infiltrates or haemorrhages, in contrast with the lungs which showed extensive interstitial oedema and mononuclear cell infiltrates, mainly CD8 T lymphocytes. As the authors justly point out, even in the title of their communication, it is now, perhaps, time to revise the sacro-saint paradigm existing since 1994 of two “different” infectious diseases caused by the same genus of rodent-borne hantaviruses of the Old and the New World, respectively. The former would target mainly the human kidney, and the latter mainly the human lung, resulting in the so-called “haemorrhagic fever with renal syndrome” (HFRS) [2] or the “hantavirus pulmonary syndrome” (HPS) [3]. When it appeared that the failing heart was, in fact, the most direct cause of death in refractory shock in HPS, yet another name, “hantavirus cardio-pulmonary syndrome” (HCPS), was added to the already bewildering list of over 60 mostly exotic synonyms for a disease described already in 1913 by Russian doctors in Vladivostok. On the other side of the Eurasian landmass and in 1934, Swedish doctors described an epidemic renal affection which they called “nephropathia epidemica” (NE), which was proven in 1979 to be, in fact, a milder variant of HFRS, caused by PUUV [4]. To date, 23 distinct species of hantaviruses have been recognized, each carried by their more or less specific rodent or insectivore reservoir. The most important pathogens are Hantaan (HTNV) and Seoul virus (SEOV) in the Far-East (where >90% of worldwide hantavirus infections occur), PUUV and Dobrava-Belgrade virus (DOBV) in Europe and Russia, and Sin Nombre (SNV) and Andes virus (ANDV) in the Americas [5]. The first HPS report that appeared in 1994 [3] described “a newly recognized disease” which was of paramount importance for a better understanding of an emerging viral infection in the New World, and generated an explosive surge in hantavirus research. However, H(C)PS was, and remains, a rare disease, with only 560 confirmed cases in the USA during the 1993–2010 period [6] (meaning 30 cases/year) and about 2,500 cases in the entire Americas, albeit with a much higher case fatality rate (CFR) of 35% [7]. This is in stark contrast with the current 0.1–0.2% CFR for PUUV infections with high morbidity in the Old World, with now over 50,000 registered NE cases in Europe, and even over 175,000 in Western Russia. In some peak years, Russia witnessed more than 10,000 cases/year (e.g. 11,413 in 1985), whereas registered NE numbers in Western Europe recently took epidemic proportions (e.g. 3,259 in Finland, 2008, and 1,874 in Germany, 2010), probably as a result of global warming [8]. Thus, it should not come as a surprise that Russian or European clinicians had or have now identified clinical characteristics claimed as being specific for “American HPS”. The Centers for Disease J. Clement (*) : P. Maes :K. Lagrou :M. Van Ranst National Reference Laboratory for Hantavirus Infections, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium e-mail: jan.clement@uzleuven.be
No takes yet. Share an insight, caveat, or question.
Clement et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: